ASCIMINIB
asciminib 20 mg tablet, 60
ASCIMINIB (13268H)
13268H
Manner of administration:Oral
Restriction 13923
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing treatment for patients without T315I mutation
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $6,175.43 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Scemblix | |||||